A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Inclusion criteria

• Have a BMI of

• ≥30 kilograms per square meter (kg/m2) or
• ≥27 kg/m2 and <30 kg/m2, with at least one of the following weight-related comorbidities:

• Hypertension
• Dyslipidemia
• Cardiovascular disease
• Obstructive sleep apnea
• Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)

Exclusion criteria

• Have a prior or planned surgical treatment for obesity
• Have at least one laboratory value suggestive of diabetes during screening
• Use of metformin, or any other glucose-lowering medications
• Have Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma
• Have poorly controlled hypertension
• Have any of the following cardiovascular conditions within 3 months prior to screening:

• acute myocardial infarction
• cerebrovascular accident (stroke)
• unstable angina, or
• hospitalization due to congestive heart failure
• Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
• Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
• Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure
• Have a history of symptomatic gallbladder disease within the past 2 years
• Have signs and symptoms of any liver disease
• Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality
• Have a history of acute or chronic pancreatitis
• Have renal impairment, measured as estimated glomerular filtration rate <30 mL/minute/1.73 m2
• Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening